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Elevated blood pressure (BP) is present in 75% of patients with acute stroke1 and is associated with increased death 
and poor functional outcome in all stroke types,2,3 recurrent 
stroke in ischemic stroke,4 and hematoma expansion in intra-
cerebral hemorrhage (ICH).5 Increased heart rate (HR) is 
similarly associated with poor outcome after acute stroke.6 
Mathematical derivations of BP and HR provide useful sum-
maries of hemodynamic parameters and include peak systolic 
BP (SBP), mean arterial pressure (MAP), pulse pressure (PP), 
PP index (PPI), rate-pressure product (RPP), and variability 
in each of them. Each parameter is associated independently 
with a worse functional outcome, death, recurrent stroke, 
Background and Purpose—Increased blood pressure (BP), heart rate, and their derivatives (variability, pulse pressure, 
rate-pressure product) are associated with poor clinical outcome in acute stroke. We assessed the effects of glyceryl 
trinitrate (GTN) on hemodynamic parameters and these on outcome in participants in the ENOS trial (Efficacy of 
Nitric Oxide in Stroke).
Methods—Four thousand and eleven patients with acute stroke and raised BP were randomized within 48 hours of onset to 
transdermal GTN or no GTN for 7 days. Peripheral hemodynamics were measured at baseline (3 measures) and daily (2 
measures) during treatment. Between-visit BP variability over days 1 to 7 (as SD) was assessed in quintiles. Functional 
outcome was assessed as modified Rankin Scale and cognition as telephone mini-mental state examination at day 90. 
Analyses were adjusted for baseline prognostic variables. Data are mean difference or odds ratios with 95% CI.
Results—Increased baseline BP (diastolic, variability), heart rate, and rate-pressure product were each associated with 
unfavorable functional outcome at day 90. Increased between-visit systolic BP variability was associated with an 
unfavourable shift in modified Rankin Scale (highest quintile adjusted odds ratio, 1.65; 95% CI, 1.37–1.99), worse cognitive 
scores (telephone mini-mental state examination: highest quintile adjusted mean difference, −2.03; 95% CI, −2.84 to 
−1.22), and increased odds of death at day 90 (highest quintile adjusted odds ratio, 1.57; 95% CI, 1.12–2.19). GTN 
lowered BP and rate-pressure product and increased heart rate at day 1 and reduced between-visit systolic BP variability.
Conclusions—Increased between-visit BP variability was associated with poor functional and cognitive outcomes and 
increased death 90 days after acute stroke. In addition to lowering BP and rate-pressure product, GTN reduced between-
visit systolic BP variability. Agents that lower BP variability in acute stroke require further study.   (Stroke. 2019;50:405-
412. DOI: 10.1161/STROKEAHA.118.023190.)
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or early neurological deterioration.7–10 Variability may be 
assessed across a set of measurements taken at 1 visit (within-
visit) or across several visits (between-visit), with different 
antihypertensive drug classes having variable effects on BP 
variability in the outpatient setting.11,12
Recent large trials assessing whether BP should be low-
ered in acute ischemic stroke were neutral.13–15 In contrast, 
lowering BP in ICH was associated with improved functional 
outcome in the INTERACT-2 (Intensive Blood Pressure 
Reduction in Acute Cerebral Hemorrhage Trial-2)16 but 
had a neutral effect in the ATACH-2 trial (Antihypertensive 
Treatment of Acute Cerebral Hemorrhage-2).17 Small phase 
II trials of glyceryl trinitrate (GTN, a nitric oxide donor) in 
acute or subacute stroke found that it lowered peripheral and 
central BP, 24 hour BP, peak SBP, PP and PPI; increased HR; 
improved vascular compliance; and did not change cerebral 
blood flow or velocity or increase intracranial pressure.18–21 
Although GTN did not modify outcome overall in the large 
ENOS trial (Efficacy of Nitric Oxide in Stroke),15 patients ran-
domized to GTN within 6 hours of onset showed a significant 
improvement in functional outcome.22,23
We assessed the association between hemodynamic meas-
ures and outcome and the hemodynamic effects of GTN in 
acute stroke using data from the ENOS trial.15
Methods
Details on the ENOS trial protocol, statistical analysis plan, base-
line characteristics, and main trial results have been published else-
where.15,24–26 In brief, ENOS recruited 4011 patients within 48 hours 
of onset of stroke symptoms with high SBP (140–220 mm Hg) to 
transdermal GTN (5 mg patch) or no patch for 7 days. In addition, 
participants taking antihypertensive medication before their stroke 
were randomized to continue or stop these drugs for 7 days. Key 
exclusion criteria included definite need to start, continue, or stop, 
BP-lowering medications; need for, or contraindication to, GTN; 
Glasgow Coma Scale <8; pure sensory stroke; isolated dysphasia; 
preceding moderate or severe dependency (modified Rankin Scale 
[mRS] 3–5); or a condition mimicking stroke.15 Patients or relatives/
carers gave written informed consent to participate. ENOS was regis-
tered (ISRCTN99414122) and approved by ethics committees/com-
petent authorities in all participating countries. The data that support 
the findings of this study are available from the corresponding author 
on reasonable request.
Hemodynamic Measurements
Peripheral BP and HR were measured using a validated automated 
monitor (Omron 705CP27) at the following timepoints: 3 measures 
at baseline (prerandomisation, day 0) and 2 on-treatment meas-
ures 1-hour postapplication of GTN patch (or at an equivalent time 
in the control group) on days 1 to 7. Values for minimum, mean, 
and maximum of the following hemodynamic derivatives were 
calculated:
PP =SBP - diastolic BP DBP( )
MAP = DBP + PP/3( )
PPI = PP/MAP
RPP =SBP HR×
Variation in measured and derived hemodynamic parameters was 
assessed as SD and coefficient of variation=(100×SD/mean).
We chose SD as the main measure of variability because of its 
common use, simplicity, and relevance to clinical practice.
The recording and interpretation of peripheral BP and HR can be 
spurious in the setting of atrial fibrillation (AF). Therefore, in addi-
tion to analyzing the whole population, sensitivity analyses were per-
formed excluding participants with AF.
The association between baseline hemodynamics and outcome 
was assessed by analyzing each baseline measure as a continuous 
variable. To assess the effect of GTN on between-visit BP variability, 
SD and coefficient of variation over days 1 to 7 were calculated for 
each of SBP, DBP, and MAP. In addition to analyzing these variables 
continuously, they were also analysed as equal quintiles with the low-
est quintile as the reference group. Correlations between mean BP 
and BP variability over days 1 to 7 were calculated using Spearman 
correlation coefficient.
Clinical Outcomes
The primary outcome of functional outcome at day 90 was meas-
ured using the 7-level mRS scale, where 0=independent and 6=dead. 
Secondary outcomes at day 90 included cognition: modified tele-
phone interview for cognition scale; telephone mini-mental state ex-
amination; and verbal fluency. Patients who had died by day 90 were 
assigned the worst score for these outcomes. Day 90 outcomes were 
assessed by trained investigators, masked to treatment allocation, via 
telephone at national coordinating centers.
Statistical Analysis
Data were analyzed by intention-to-treat in line with the ENOS trial 
statistical analysis plan26 and statistical analyses adopted in the pri-
mary publication.15 Data are number (%), median (interquartile 
range), or mean (SD). Baseline characteristics between groups were 
assessed using χ2 for categorical variables and 1-way ANOVA for 
continuous variables.
Comparisons between hemodynamics and outcome overall and 
between treatment groups were assessed using ANCOVA, binary 
logistic regression, ordinal logistic regression, or multiple linear 
regression. Statistical models were adjusted for prognostic base-
line covariates: age, sex, baseline mRS, history of previous stroke, 
history of diabetes mellitus, final diagnosis, prior nitrate use, total 
anterior circulation syndrome, baseline Scandinavian Stroke Scale, 
thrombolysis, feeding status, time to randomization, and baseline 
SBP. Analyses involving the whole population were also adjusted 
for treatment allocation. The resultant odds ratio or mean differ-
ence and associated 95% CI are given, with significance set at 
P≤0.05. Odds ratios were calculated for change in hemodynamic 
variables of 1, 10, or 100 units as appropriate for each variable in 
continuous analyses. Analyses were performed using SPSS version 
22 (Chicago, IL).
Results
The ENOS trial enrolled 4011 patients with acute stroke, with 
mean age 70.3 (12.2) years, male sex 2297 (57.3%), severity 
Scandinavian Stroke Scale 33.7 (13.1), and time from onset 
to randomization 26 (21) hours. Those randomized to con-
tinue or stop their antihypertensives were balanced between 
GTN versus no GTN groups.15 Baseline hemodynamics did 
not differ between GTN and no GTN groups (Table I in 
the online-only Data Supplement), with overall mean BP 
167.3/89.5 mm Hg and HR 77.5 bpm; 762 (19.0%) of par-
ticipants had AF.
Baseline Hemodynamics and Functional Outcome
Higher baseline values of DBP, MAP, HR, and RPP were as-
sociated with unfavorable shifts in mRS at day 90 in adjusted 
analyses (Table 1). However, in a sensitivity analysis excluding 
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participants with AF, only increasing HR, RPP, and their var-
iability were associated with unfavorable shifts in functional 
outcome.
Between-Visit BP Variability Over 
Days 1 to 7 and Outcome
The highest quintile of between-visit variability of SBP 
(SD) over days 1 to 7 was associated with an unfavourable 
shift in mRS (odds ratio, 1.65; 95% CI, 1.37–1.99; P<0.001; 
Figure 1) and increased risk of death at day 90 (odds ratio 
1.57; 95% CI, 1.12–2.19; P=0.009). These associations were 
maintained when participants with AF were excluded and 
when analyzed as a continuous variable. Similarly, the highest 
quintile was also associated with worse cognitive scores at day 
90 compared with the lowest quintile: telephone mini-mental 
state examination mean difference, −2.03; 95% CI, −2.84 
to −1.22; P<0.001; modified telephone interview for cogni-
tion scale mean difference, −2.68; 95% CI −3.84 to −1.51; 
P<0.001; verbal fluency mean difference, −1.87; 95% CI, 
−2.73 to −1.00; P<0.001 (Figure 2). These associations were 
maintained after excluding participants with AF. Furthermore, 
analogous associations with these outcomes were seen across 
all measures of between-visit BP variability for SBP (Figure I 
in the online-only Data Supplement), DBP (Figures II and III 
in the online-only Data Supplement), and MAP (Figures IV 
and V in the online-only Data Supplement).
Mean SBP over days 1 to 7 was weakly correlated with 
measures of between-visit SBP variability (Spearman correla-
tion coefficient: SD, 0.137; coefficient of variation, −0.155). 
Similar weak correlations between mean DBP and MAP and 
their corresponding measures of variability were seen. In 
addition, there was no correlation between within-individual 
BP trend over the treatment period and mRS at day 90, high-
lighting that the associations between variability and outcome 
seen were not mediated by trend in mean BP over time.
Hemodynamic Effects of GTN
Table 2 shows the effect of GTN versus no GTN on hemo-
dynamic parameters at day 1 that is, on treatment (n=3851, 
96%). Overall, GTN lowered mean BP by 7/3.6 mm Hg, MAP 
by 4.7 mm Hg, and PP by 3.4 mm Hg. GTN increased HR 
by 1.4 bpm but reduced RPP (the product of SBP and HR). 
GTN had no effect on within-visit variability of any hemo-
dynamic variable at day 1. The hemodynamic effects of GTN 
Figure 1. Effect of systolic blood pressure (SBP) variability over days 1 to 7 on modified Rankin Scale (mRS) and death at day 90. Quintiles of SBP variability 
over days 1 to 7 (reference=first quintile) vs (A) mRS at day 90 overall unadjusted (n=3978), (B) overall adjusted (n=3978), (C) excluding atrial fibrillation (AF) 
participants adjusted (n=3221), (D) death at day 90 overall (n=3982). Ordinal or binary logistic regression. Data are odds ratio with 95% CI. GTN indicates 
glyceryl trinitrate.
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were maintained in those without AF (Table II in the online-
only Data Supplement). GTN lowered mean BP by 6.8/3.4 
mm Hg in ischemic stroke patients and by 7.5/4.9 mm Hg in 
those with ICH at day 1 and reduced within-visit variability of 
SBP (SD) at day 1 by 1.3 mm Hg in those with ICH, but not 
in ischemic stroke.
Over 7 days of treatment, GTN lowered mean BP by 
2.9/2.1 mm Hg, MAP by 2.3 mm Hg, PP by 0.8 mm Hg, and 
increased HR by 1 bpm on average (Table III in the online-
only Data Supplement). These results are dampened in com-
parison to the day 1 data (Table 2), highlighting tachyphylaxis 
seen with GTN over time. GTN lowered between-visit vari-
ability of SBP (SD) over days 1 to 7 by 0.4 mm Hg overall 
and by 1.1 mm Hg in those with ICH. In contrast, GTN did 
not change SBP coefficient of variation or between-visit vari-
ability of DBP. These effects were maintained in those without 
AF (Table IV in the online-only Data Supplement).
Discussion
In this prespecified secondary analysis of ENOS trial data, 
baseline hemodynamic parameters were associated with worse 
functional outcome at day 90. Increased between-visit BP var-
iability over days 1 to 7 was associated with worse functional 
and cognitive outcomes and increased odds of death at day 
90. GTN lowered BP and RPP despite increasing HR at day 1 
and reduced between-visit variability of SBP over days 1 to 7.
Several secondary analyses of large trials have demon-
strated associations between both high and low BP and poor 
clinical outcomes after acute ischemic stroke.2,8,28 Although 
we found no association between baseline SBP and functional 
outcome, increased maximum DBP and MAP were both in-
dependently associated with an unfavorable shift in mRS at 
day 90. Although 1 cohort found that baseline MAP—and not 
DBP—was associated with death or dependency at 90 days,8 
others have reported no effect of DBP on early outcomes at 
day 10.9
All derived measures of higher baseline HR and RPP were 
associated with an unfavorable shift in mRS at day 90, both 
overall and in those without AF. High baseline HR is associ-
ated with increased death, heart failure and dependency at 90 
days in both acute ischemic and hemorrhagic stroke.6,29,30 High 
baseline HR is a surrogate for clinical frailty and comorbidity 
burden31 but may also represent underlying dehydration, 
anemia and stroke severity, which are all independently asso-
ciated with poor prognosis after stroke.32,33 Although there are 
fewer data pertaining to RPP in acute stroke, increased base-
line RPP has been associated with death or dependency at day 
90.8 In addition to confirming this finding, we demonstrated 
that increased within-visit variability of RPP at baseline was 
associated with an unfavorable shift in mRS, a novel finding 
in acute stroke.
Increased between-visit variability of SBP over days 1 to 7 
was associated with an unfavorable shift in mRS, worse cogni-
tive scores, and increased odds of death at day 90 independent 
of trend in mean BP over time. Therefore, fluctuations in BP 
in the days after stroke may have a greater influence on 90-day 
outcome than absolute mean BP; in line with a recently re-
ported analysis in ICH patients.34 We add to the growing body 
of evidence that increased between-visit BP variability (SBP, 
DBP, and MAP) is associated with poor clinical outcome after 
acute stroke.7,10 Furthermore, we report novel associations 
with increased between-visit BP variability and worse cogni-
tive scores at 90 days across 3 cognitive domains.
Using data from one of the largest BP-lowering trials in 
acute stroke, we have confirmed transdermal GTN’s afore-
mentioned effects on hemodynamics.21 The significant reduc-
tion in RPP at day 1, implies that GTN’s ability to increase 
HR is negated by its BP-lowering effect. GTN significantly 
lowered between-visit variability of SBP over days 1 to 7, mir-
roring a similar finding in a pooled analysis of 4 GTN pilot 
studies.35 Whether this modest reduction is sufficient to impact 
upon clinical outcome requires further testing.
The timing of hemodynamic measurements in rela-
tion to stroke onset is important. The maintenance of cere-
bral blood flow through autoregulation is impaired in acute 
stroke with cerebral perfusion pressure becoming dependent 
on systemic BP.36 Potentially viable brain tissue may, there-
fore, be sensitive to greater variability in BP with peaks 
increasing the risk of hemorrhagic transformation in is-
chemic stroke or hematoma expansion in ICH, and cerebral 
Figure 2. Effect of systolic blood pressure (SBP) variability over days 1 to 7 on cognition at day 90. Quintiles of SBP variability over days 1 to 7 
(reference=first quintile) vs (A) telephone mini-mental state examination (t-MMSE; n=2019), (B) modified telephone interview for cognition scale (TICS-M; 
n=2001), (C) verbal fluency (n=2352). Multiple linear regression with adjustment for baseline prognostic covariates. Data are mean difference with 95% CI. 
GTN indicates glyceryl trinitrate.
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edema in both stroke types, whereas troughs cause further 
ischemic injury.5,10 If so, then medications that lower BP 
variability may be best assessed as early as possible after 
stroke onset before these effects manifest. Although this po-
tential time-dependent mechanism is speculative, it may be 1 
way in which GTN may exert its apparent beneficial impact 
on clinical outcomes.35 Furthermore, GTN reduces arterial 
stiffness,35 which is independently associated with hemor-
rhagic transformation37 and poor collateral status38 in acute 
ischemic stroke. The efficacy of transdermal GTN given 
within 4 hours of onset is currently being assessed in the 
large RIGHT-2 (Rapid Intervention With Glyceryl Trinitrate 
in Hypertensive Stroke Trial 2).39
The strengths of the present study include: its large sample 
size using data from one of the largest BP trials in acute stroke; 
the use of prespecified analyses and ordinal logistic regression 
to increase power compared with binary analysis of mRS; and 
generalisability with analyses including the vast majority of 
Table 1. Baseline Hemodynamics Versus mRS at Day 90, Overall and Excluding Those With AF
 n
Overall Unadjusted  
OR (95% CI) P Value
Overall Adjusted  
OR (95% CI) P Value n
Excluding AF: Adjusted 
OR (95% CI) P Value
SBP min, mm Hg* 3995 1.04 (1.01–1.07) 0.014† 1.02 (0.99–1.05) 0.30 3234 1.02 (0.99–1.05) 0.31
SBP mean, mm Hg* 3995 1.05 (1.02–1.08) 0.001† 1.02 (0.99–1.05) 0.16 3234 1.02 (0.99–1.06) 0.19
SBP max, mm Hg* 3995 1.05 (1.02–1.08) <0.001† 1.02 (1.00–1.05) 0.11 3234 1.02 (0.99–1.05) 0.16
SBP SD, mm Hg 3990 1.02 (1.01–1.03) 0.004† 1.01 (1.00–1.02) 0.13 3228 1.01 (1.00–1.02) 0.23
SBP CV (%) 3990 1.02 (1.00–1.04) 0.014† 1.01 (1.00–1.03) 0.15 3228 1.01 (0.99–1.03) 0.24
MAP min, mm Hg* 3995 0.95 (0.91–0.99) 0.012† 1.03 (0.98–1.07) 0.24 3234 1.02 (0.97–1.07) 0.50
MAP mean, mm Hg* 3995 0.98 (0.94–1.02) 0.27 1.04 (1.00–1.09) 0.07 3234 1.03 (0.98–1.08) 0.32
MAP max, mm Hg* 3995 1.01 (0.97–1.05) 0.65 1.05 (1.01–1.09) 0.017† 3234 1.03 (0.99–1.08) 0.17
MAP SD, mm Hg 3990 1.04 (1.03–1.06) <0.001† 1.02 (1.01–1.04) 0.009† 3229 1.01 (1.00–1.03) 0.13
MAP CV (%) 3990 1.05 (1.04–1.07) <0.001† 1.02 (1.01–1.04) 0.012† 3229 1.02 (1.00–1.04) 0.13
DBP min, mm Hg* 3995 0.88 (0.84–0.91) <0.001† 1.02 (0.97–1.07) 0.40 3234 1.00 (0.95–1.05) 0.95
DBP mean, mm Hg* 3995 0.92 (0.88–0.96) <0.001† 1.04 (1.00–1.09) 0.08 3234 1.01 (0.96–1.07) 0.59
DBP max, mm Hg* 3995 0.97 (0.94–1.01) 0.14 1.05 (1.01–1.09) 0.017† 3234 1.02 (0.98–1.07) 0.32
DBP SD, mm Hg 3990 1.04 (1.03–1.06) <0.001† 1.02 (1.01–1.03) 0.006† 3229 1.01 (1.00–1.03) 0.12
DBP CV (%) 3990 1.04 (1.03–1.06) <0.001† 1.02 (1.00–1.03) 0.007† 3229 1.01 (1.00–1.02) 0.08
HR min, bpm* 3991 1.13 (1.09–1.18) <0.001† 1.10 (1.06–1.14) <0.001† 3231 1.11 (1.06–1.16) <0.001†
HR mean, bpm* 3991 1.16 (1.12–1.21) <0.001† 1.11 (1.07–1.16) <0.001† 3231 1.12 (1.07–1.17) <0.001†
HR max, bpm* 3991 1.17 (1.13–1.21) <0.001† 1.11 (1.07–1.15) <0.001† 3231 1.12 (1.08–1.17) <0.001†
HR SD, bpm 3986 1.05 (1.03–1.07) <0.001† 1.03 (1.01–1.04) 0.001† 3226 1.02 (1.00–1.04) 0.020†
HR CV (%) 3986 1.03 (1.02–1.05) <0.001† 1.02 (1.01–1.03) 0.005† 3226 1.01 (1.00–1.03) 0.10
PP min, mm Hg * 3995 1.07 (1.04–1.10) <0.001† 0.99 (0.96–1.02) 0.47 3234 1.01 (0.97–1.04) 0.78
PP mean, mm Hg* 3995 1.12 (1.09–1.16) <0.001† 1.01 (0.97–1.04) 0.79 3234 1.02 (0.98–1.06) 0.25
PP max, mm Hg * 3995 1.13 (1.10–1.16) <0.001† 1.01 (0.98–1.04) 0.62 3234 1.02 (0.99–1.06) 0.24
PP SD, mm Hg 3990 1.02 (1.02–1.03) <0.001† 1.01 (1.00–1.02) 0.06 3229 1.01 (1.00–1.02) 0.20
PP CV (%) 3990 1.01 (1.01–1.02) <0.001† 1.01 (1.00–1.01) 0.13 3229 1.00 (1.00–1.01) 0.48
PPI mean 3995 4.02 (2.80–5.77) <0.001† 0.88 (0.59–1.30) 0.51 3234 1.16 (0.73–1.83) 0.53
RPP min, mm Hg·bpm‡ 3991 1.01 (1.01–1.01) <0.001† 1.01 (1.00–1.01) <0.001† 3231 1.01 (1.00–1.01) <0.001†
RPP mean, mm Hg·bpm‡ 3991 1.01 (1.01–1.01) <0.001† 1.01 (1.00–1.01) <0.001† 3231 1.01 (1.00–1.01) <0.001†
RPP max, mm Hg·bpm‡ 3991 1.01 (1.01–1.01) <0.001† 1.01 (1.00–1.01) <0.001† 3231 1.01 (1.00–1.01) <0.001†
RPP SD, mm Hg·bpm‡ 3986 1.03 (1.02–1.03) <0.001† 1.02 (1.01–1.02) <0.001† 3226 1.01 (1.00–1.02) 0.006†
RPP CV (%) 3986 1.03 (1.02–1.04) <0.001† 1.02 (1.01–1.03) 0.001† 3226 1.01 (1.00–1.02) 0.08
Ordinal logistic regression adjusted for baseline prognostic covariates. AF indicates atrial fibrillation; CV, coefficient of variation; DBP, diastolic blood pressure; HR, 
heart rate; MAP, mean arterial pressure; max, maximum; min, minimum; mRS, modified Rankin Scale; OR, odds ratio; PP, pulse pressure; PPI, pulse pressure index; 
RPP, rate-pressure product; and SBP, systolic blood pressure.
*OR per 10 units change.
†Significance P ≤0.05.
‡OR per 100 units change.
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recruited participants from a variety of countries, stroke serv-
ices, and patient populations.
This study has several limitations. First, some compari-
sons were observational, and the results should be interpreted 
with caution because of the inherent risk of confounding. 
Despite adjusting for baseline prognostic factors, we cannot 
exclude reverse causality, for example, if patients with larger, 
more severe strokes also had increased BP variability. Second, 
the inclusion criterion of SBP 140 to 220 mm Hg systemati-
cally excluded patients and thus reduces generalisability, al-
though this is likely to have attenuated rather than enhanced 
the strength of reported associations. Third, although a vali-
dated automated monitor was used for measurements, beat-
to-beat data were not available, limiting the ability to detect 
within-visit variability. Fourth, a minority of patients had AF 
which can reduce the accuracy of hemodynamic measure-
ments; however, sensitivity analyses excluding patients with 
AF were performed to account for this. Fifth, cognitive out-
come data were only available for around 50% of participants, 
and their analyses may have lacked power, weakening the 
observed associations but given the severity of the stroke pop-
ulation recruited this is inevitable. Lastly, participants were 
recruited a median of 26 hours after stroke onset: longer than 
previous studies that have detected associations between he-
modynamic measures and functional outcome.10
Smooth lowering of elevated BP with avoidance of 
peaks and troughs over the first days after stroke should be 
considered by clinicians in both acute ischemic and hem-
orrhagic stroke. Whether smooth and sustained BP control 
is beneficial has yet to be tested directly in randomized 
Table 2. Effect of GTN Versus No GTN on Hemodynamic Variables at Day 1
 GTN No GTN
Unadjusted Mean Difference 
(95% CI) P Value Adjusted Mean Difference (95% CI) P Value
Patient, N 1914 1937     
SBP min 152.9 (22.7) 159.9 (22.8) −7.03 (−8.47 to −5.59) <0.001* −6.92 (−8.11 to −5.72) <0.001*
SBP mean 156.6 (22.6) 163.6 (22.5) −7.03 (−8.45 to −5.61) <0.001* −6.98 (−8.12 to −5.84) <0.001*
SBP max 160.4 (23.2) 167.4 (22.9) −7.03 (−8.49 to −5.57) <0.001* −6.98 (−8.17 to −5.80) <0.001*
SBP SD 5.9 (5.9) 5.9 (6.4) 0.01 (−0.40 to 0.42) 0.96 −0.03 (−0.41 to 0.40) 0.99
SBP CV (%) 3.8 (3.9) 3.6 (4.1) 0.15 (−0.12 to 0.41) 0.28 0.14 (−0.13 to 0.40) 0.31
MAP min 106.1 (15.2) 110.6 (15.3) −4.57 (−5.53 to −3.61) <0.001* −4.59 (−5.38 to −3.8) <0.001*
MAP mean 108.4 (15.2) 113.1 (15.1) −4.65 (−5.61 to −3.69) <0.001* −4.72 (−5.49 to −3.95) <0.001*
MAP max 110.8 (15.7) 115.5 (15.6) −4.73 (−5.72 to −3.75) <0.001* −4.79 (−5.62 to −3.97) <0.001*
MAP SD 3.7 (4.0) 3.8 (4.2) −0.12 (−0.4 to 0.15) 0.38 −0.13 (−0.40 to 0.14) 0.35
MAP CV (%) 3.4 (3.7) 3.4 (3.9) 0.03 (−0.23 to 0.28) 0.84 0.02 (−0.24 to 0.27) 0.91
DBP min 81.7 (14.1) 85.1 (14.6) −3.39 (−4.30 to −2.49) <0.001* −3.39 (−4.11 to −2.67) <0.001*
DBP mean 84.3 (14.1) 87.8 (14.5) −3.46 (−4.37 to −2.56) <0.001* −3.59 (−4.3 to −2.88) <0.001*
DBP max 87.0 (14.9) 90.5 (15.3) −3.53 (−4.48 to −2.58) <0.001* −3.71 (−4.51 to −2.90) <0.001*
DBP SD 4.2 (4.8) 4.3 (4.9) −0.10 (−0.42 to 0.22) 0.53 −0.12 (−0.44 to 0.20) 0.47
DBP CV (%) 4.9 (5.5) 4.9 (5.5) 0.07 (−0.30 to 0.43) 0.71 0.04 (−0.32 to 0.41) 0.81
HR min 77.2 (15.0) 75.6 (14.8) 1.61 (0.67 to 2.55) 0.001* 1.31 (0.68 to 1.94) <0.001*
HR mean 79.0 (15.1) 77.3 (14.9) 1.68 (0.73 to 2.63) 0.001* 1.35 (0.73 to 1.96) <0.001*
HR max 80.7 (15.6) 79.0 (15.5) 1.74 (0.76 to 2.73) 0.001* 1.42 (0.75 to 2.09) <0.001*
HR SD 2.8 (4.0) 2.7 (3.8) 0.10 (−0.16 to 0.36) 0.44 0.10 (−0.16 to 0.35) 0.45
HR CV (%) 3.5 (4.9) 3.5 (4.8) 0.07 (−0.25 to 0.39) 0.68 0.06 (−0.26 to 0.38) 0.71
PP 72.3 (17.9) 75.9 (19.0) −3.57 (−4.74 to −2.40) <0.001* −3.38 (−4.26 to −2.51) <0.001*
PPI 0.67 (0.16) 0.68 (0.16) −0.01 (−0.02 to 0.01) 0.33 0.00 (−0.01 to 0.01) 0.48
RPP min 11945.6 (3001.3) 12241.8 (3067.4) −296.21 (−488.22 to −104.2) 0.003* −323.14 (−464.77 to −181.51) <0.001*
RPP mean 12386.5 (3054.9) 12664.0 (3104.4) −277.50 (−472.37 to −82.63) 0.005* −318.67 (−458.12 to −179.22) <0.001*
RPP max 12827.4 (3210.0) 13086.2 (3238.8) −258.79 (−462.8 to −54.77) 0.013* −300.61 (−452.78 to −148.44) <0.001*
RPP SD 689.7 (818.7) 661.4 (805.3) 28.29 (−82.34 to 25.77) 0.31 25.42 (−27.86 to 78.70) 0.35
RPP CV (%) 5.6 (6.3) 5.3 (6.4) 0.28 (−0.14 to 0.71) 0.19 0.27 (−0.15 to 0.69) 0.21
ANCOVA adjusted for baseline variable. CV indicates coefficient of variation; DBP, diastolic blood pressure; GTN, glyceryl trinitrate; HR, heart rate; MAP, mean arterial 
pressure; max, maximum; min, minimum; PP, pulse pressure; PPI, pulse pressure index; RPP, rate-pressure product; and SBP, systolic blood pressure.
*Significance P≤0.05.
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controlled trials. If BP variability is a modifiable target in 
acute stroke, then agents that lower it, including GTN, may 
be of benefit.
Acknowledgments
We thank the participants, investigators, and research staff involved 
in the ENOS trial (Efficacy of Nitric Oxide in Stroke). J.P. Appleton 
wrote the first draft and performed the analyses. P.M. Bath con-
ceived the study, amended the article, and is the project guarantor. All 
authors commented on and approved the article.
Sources of Funding
ENOS (Efficacy of Nitric Oxide in Stroke) was funded by the British 
United Provident Association UK Foundation and Medical Research 
Council (G0501797). J.P. Appleton is funded by National Institute 
for Health Research TARDIS (10/104/24) trial (Triple Antiplatelets 
for Reducing Dependency after Ischaemic Stroke) and British Heart 
Foundation RIGHT-2 (Rapid Intervention With Glyceryl Trinitrate in 
Hypertensive Stroke Trial 2; CS/14/4/30972).
Disclosures
P.M. Bath is Stroke Association Professor of Stroke Medicine and 
Chief Investigator of the ENOS trial (Efficacy of Nitric Oxide in 
Stroke) and RIGHT-2 (Rapid Intervention With Glyceryl Trinitrate 
in Hypertensive Stroke Trial 2). P.M. Bath and P.M. Rothwell are 
National Institute for Health Research Senior Investigators. The other 
authors report no conflicts
References
 1. Oppenheimer S, Hachinski V. Complications of acute stroke. Lancet. 
1992;339:721–724.
 2. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA; IST Collaborative 
Group. Blood pressure and clinical outcomes in the International Stroke 
Trial. Stroke. 2002;33:1315–1320.
 3. Vemmos KN, Tsivgoulis G, Spengos K, Zakopoulos N, Synetos A, 
Manios E, et al. U-shaped relationship between mortality and ad-
mission blood pressure in patients with acute stroke. J Intern Med. 
2004;255:257–265.
 4. Sprigg N, Gray LJ, Bath PM, Boysen G, De Deyn PP, Friis P, et al; 
TAIST Investigators. Relationship between outcome and baseline 
blood pressure and other haemodynamic measures in acute ischaemic 
stroke: data from the TAIST trial. J Hypertens. 2006;24:1413–1417. doi: 
10.1097/01.hjh.0000234123.55895.12
 5. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute 
stroke and subsequent outcome: a systematic review. Hypertension. 
2004;43:18–24. doi: 10.1161/01.HYP.0000105052.65787.35
 6. Nolte C, Erdur H, Grittner U, Schneider A, Piper S, Scheitz J, et al; 
VISTA Collaborators. Impact of heart rate on admission on mortality 
and morbidity in acute ischaemic stroke patients - results from VISTA. 
Eur J Neurol. 2016;23:1750–1756. doi: 10.1111/ene.13115
 7. Manning L, Hirakawa Y, Arima H, Wang X, Chalmers J, Wang J, et al; 
INTERACT2 Investigators. Blood pressure variability and outcome after 
acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, 
a randomised controlled trial. Lancet Neurol. 2014;13:364–373. doi: 
10.1016/S1474-4422(14)70018-3
 8. Sare GM, Ali M, Shuaib A, Bath PM; VISTA Collaboration. Relationship 
between hyperacute blood pressure and outcome after ischemic stroke: 
data from the VISTA collaboration. Stroke. 2009;40:2098–2103. doi: 
10.1161/STROKEAHA.108.539155
 9. Geeganage C, Tracy M, England T, Sare G, Moulin T, Woimant F, et 
al; for TAIST Investigators. Relationship between baseline blood pres-
sure parameters (including mean pressure, pulse pressure, and vari-
ability) and early outcome after stroke: data from the Tinzaparin in 
Acute Ischaemic Stroke Trial (TAIST). Stroke. 2011;42:491–493. doi: 
10.1161/STROKEAHA.110.596163
 10. Manning LS, Rothwell PM, Potter JF, Robinson TG. Prognostic signifi-
cance of short-term blood pressure variability in acute stroke: system-
atic review. Stroke. 2015;46:2482–2490. doi: 10.1161/STROKEAHA. 
115.010075
 11. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihyperten-
sive-drug class on interindividual variation in blood pressure and risk of 
stroke: a systematic review and meta-analysis. Lancet. 2010;375:906–
915. doi: 10.1016/S0140-6736(10)60235-8
 12. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, 
et al; ASCOT-BPLA and MRC Trial Investigators. Effects of beta block-
ers and calcium-channel blockers on within-individual variability in 
blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–480. doi: 
10.1016/S1474-4422(10)70066-1
 13. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, et al; 
SCAST Study Group. The angiotensin-receptor blocker candesar-
tan for treatment of acute stroke (SCAST): a randomised, placebo-
controlled, double-blind trial. Lancet. 2011;377:741–750. doi: 
10.1016/S0140-6736(11)60104-9
 14. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al; CATIS 
Investigators. Effects of immediate blood pressure reduction on death 
and major disability in patients with acute ischemic stroke: the CATIS 
randomized clinical trial. JAMA. 2014;311:479–489. doi: 10.1001/jama. 
2013.282543
 15. Bath P, Woodhouse L, Scutt P, Krishnan K, Wardlaw J, Bereczki D, et 
al. Efficacy of nitric oxide, with or without continuing antihyperten-
sive treatment, for management of high blood pressure in acute stroke 
(enos): a partial-factorial randomised controlled trial. The Lancet. 
2015;385:617–628.
 16. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al; 
INTERACT2 Investigators. Rapid blood-pressure lowering in patients 
with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355–
2365. doi: 10.1056/NEJMoa1214609
 17. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, 
et al; ATACH-2 Trial Investigators and the Neurological Emergency 
Treatment Trials Network. Intensive blood-pressure lowering in patients 
with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033–1043. 
doi: 10.1056/NEJMoa1603460
 18. Bath PM, Pathansali R, Iddenden R, Bath FJ. The effect of transdermal 
glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet 
function in acute stroke. Cerebrovasc Dis. 2001;11:265–272. doi: 
10.1159/000047649
 19. Rashid P, Weaver C, Leonardi-Bee J, Bath F, Fletcher S, Bath P. The 
effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood 
pressure, cerebral and cardiac hemodynamics, and plasma nitric oxide 
levels in acute stroke. J Stroke Cerebrovasc Dis. 2003;12:143–151. doi: 
10.1016/S1052-3057(03)00037-5
 20. Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PM. 
Transdermal glyceryl trinitrate lowers blood pressure and maintains ce-
rebral blood flow in recent stroke. Hypertension. 2006;47:1209–1215. 
doi: 10.1161/01.HYP.0000223024.02939.1e
 21. Gray LJ, Sprigg N, Kaur L, Stear H, Hammonds F, Bath PMW. The 
efficacy of nitric oxide in stroke (ENOS) trial: baseline characteris-
tics of the first 474 patients included in the start-up phase. Int J Stroke. 
2006;1:111–174.
 22. Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, 
et al; ENOS Investigators. Effect of hyperacute administration (within 
6 hours) of transdermal glyceryl trinitrate, a nitric oxide donor, on 
outcome after stroke: subgroup analysis of the Efficacy of Nitric 
Oxide in Stroke (ENOS) Trial. Stroke. 2015;46:3194–3201. doi: 
10.1161/STROKEAHA.115.009647
 23. Ankolekar S, Fuller M, Cross I, Renton C, Cox P, Sprigg N, et al. 
Feasibility of an ambulance-based stroke trial, and safety of glyceryl 
trinitrate in ultra-acute stroke: the rapid intervention with glyceryl trini-
trate in Hypertensive Stroke Trial (RIGHT, ISRCTN66434824). Stroke. 
2013;44:3120–3128. doi: 10.1161/STROKEAHA.113.001301
 24. ENOS Trial Investigators. Glyceryl trinitrate vs. control, and contin-
uing vs. stopping temporarily prior antihypertensive therapy, in acute 
stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke 
(ENOS) trial (ISRCTN99414122). Int J Stroke. 2006;1:245–249. doi: 
XXX10.1111/j.1747-4949.2006.00059.x
 25. ENOS Investigators. Baseline characteristics of the 4011 patients 
recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial. Int J 
Stroke. 2014;9:711–720. doi: 10.1111/ijs.12308
 26. Bath PM, Houlton A, Woodhouse L, Sprigg N, Wardlaw J, Pocock 
S; ENOS Trialists. Statistical analysis plan for the ‘Efficacy of Nitric 
Oxide in Stroke’ (ENOS) trial. Int J Stroke. 2014;9:372–374. doi: 
10.1111/ijs.12235
 27. O’Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices 
for self-measurement of blood pressure according to the revised British 
D
ow
nloaded from
 http://ahajournals.org by on July 26, 2019
412  Stroke  February 2019
Hypertension Society Protocol: the Omron HEM-705CP, Philips 
HP5332, and Nissei DS-175. Blood Press Monit. 1996;1:55–61.
 28. Berge E, Cohen G, Lindley RI, Sandercock P, Wardlaw JM, Sandset 
EC, et al. Effects of blood pressure and blood pressure-lowering 
treatment during the first 24 hours among patients in the third inter-
national stroke trial of thrombolytic treatment for acute ischemic 
stroke. Stroke. 2015;46:3362–3369. doi: 10.1161/STROKEAHA. 
115.010319
 29. Tomii Y, Toyoda K, Suzuki R, Naganuma M, Fujinami J, Yokota C, et 
al. Effects of 24-hour blood pressure and heart rate recorded with am-
bulatory blood pressure monitoring on recovery from acute ischemic 
stroke. Stroke. 2011;42:3511–3517. doi: 10.1161/STROKEAHA. 
111.628586
 30. Qiu M, Sato S, Zheng D, Wang X, Carcel C, Hirakawa Y, et al; 
INTERACT Investigators*. Admission heart rate predicts poor outcomes 
in acute intracerebral hemorrhage: the intensive blood pressure reduction 
in acute cerebral hemorrhage trial studies. Stroke. 2016;47:1479–1485. 
doi: 10.1161/STROKEAHA.115.012382
 31. Ramsay SE, Arianayagam DS, Whincup PH, Lennon LT, Cryer J, 
Papacosta AO, et al. Cardiovascular risk profile and frailty in a popu-
lation-based study of older British men. Heart. 2015;101:616–622. doi: 
10.1136/heartjnl-2014-306472
 32. Rowat A, Graham C, Dennis M. Dehydration in hospital-admitted stroke 
patients: detection, frequency, and association. Stroke. 2012;43:857–859. 
doi: 10.1161/STROKEAHA.111.640821
 33. Milionis H, Papavasileiou V, Eskandari A, D’Ambrogio-Remillard 
S, Ntaios G, Michel P. Anemia on admission predicts short- and 
long-term outcomes in patients with acute ischemic stroke. Int J Stroke. 
2015;10:224–230. doi: 10.1111/ijs.12397
 34. Chung PW, Kim JT, Sanossian N, Starkmann S, Hamilton S, Gornbein J, 
et al; FAST-MAG Investigators and Coordinators. Association between 
hyperacute stage blood pressure variability and outcome in patients with 
spontaneous intracerebral hemorrhage. Stroke. 2018;49:348–354. doi: 
10.1161/STROKEAHA.117.017701
 35. Appleton JP, Sprigg N, Bath PM. Therapeutic potential of transder-
mal glyceryl trinitrate in the management of acute stroke. CNS Drugs. 
2017;31:1–9. doi: 10.1007/s40263-016-0387-7
 36. Tikhonoff V, Zhang H, Richart T, Staessen JA. Blood pressure as a prog-
nostic factor after acute stroke. Lancet Neurol. 2009;8:938–948. doi: 
10.1016/S1474-4422(09)70184-X
 37. Acampa M, Camarri S, Lazzerini PE, Guideri F, Tassi R, Valenti R, et 
al. Increased arterial stiffness is an independent risk factor for hemor-
rhagic transformation in ischemic stroke undergoing thrombolysis. Int J 
Cardiol. 2017;243:466–470. doi: 10.1016/j.ijcard.2017.03.129
 38. Acampa M, Romano DG, Lazzerini PE, Leonini S, Guideri F, Tassi R, 
et al. Increased arterial stiffness is associated with poor collaterals in 
acute ischemic stroke from large vessel occlusion. Curr Neurovasc Res. 
2018;15:34–38. doi: 10.2174/1567202615666180326100347
 39. Appleton JP, Scutt P, Dixon M, Howard H, Haywood L, Havard D, et al; 
RIGHT-2 Investigators. Ambulance-delivered transdermal glyceryl trini-
trate versus sham for ultra-acute stroke: rationale, design and protocol 
for the rapid intervention with glyceryl trinitrate in hypertensive stroke 
trial-2 (RIGHT-2) trial (ISRCTN26986053) [published online January 1, 
2017]. Int J Stroke. doi: 10.1177/1747493017724627
D
ow
nloaded from
 http://ahajournals.org by on July 26, 2019
